Page 2 - Between Aug News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Surat: A 32-year-old Dindoli resident lost Rs 1.

1. Absence of moderate or severe headache 24 hours following administration of treatment drug was significantly greater among patients with migraine attacks that were treated with ubrogepant during the prodrome phase. 2. Adverse events were slightly more frequent in the ubrogepant group versus placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Ubrogepant, a calcitonin gene-related

1. Patients in the primaquine group reported a significant reduction in parasitemia risk at day 63 compared to those in the standard care group. 2. The majority of adverse events were mild-to-moderate with no treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: In areas where Plasmodium vivax and Plasmodium falciparum coexist, there exists an

1. All-cause mortality after 5 years was similar for patients in the adaptive and conventional CRT groups. 2. System-related adverse events exhibited no significant disparity between groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Cardiac resynchronization therapy (CRT) is the standard of care among patients with decompensated heart failure and left bundle branch block. However,

1. Sleep restriction therapy was superior to sleep hygiene for the management of chronic insomnia. 2. There were no treatment-related adverse events. Evidence Rating Level: 1 (Excellent) Study Rundown: Insomnia is a chronic disorder affecting 10% of people worldwide. Although cognitive behavioural therapy (CBT) remains the primary treatment for insomnia, access to this is scarce.